Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.17 - $63.12
Previous CloseN/A
Volume11.83K
Average Volume (3M)152.92K
Market Cap
$651.08M
Enterprise Value$193.21M
Total Cash (Recent Filing)$70.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Apr 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding11,059,665
10 Day Avg. Volume200,122
30 Day Avg. Volume152,920
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-2.46
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.81
Forecast
1Y Price Target
$73.00Price Target Upside26.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Market ExpansionAdding another indication and expanding the addressable market for QTORIN rapamycin by approximately 40% provides further opportunity to validate its use in multiple mTOR driven diseases.
Physician Adoption96% of surveyed physicians indicated they would incorporate an approved 3.9% w/w topical rapamycin into their practice in treating CSAs.
Bears Say
Adverse EventsThe review makes clear that while efficacy is seen, systemic delivery of sirolimus is constrained by frequent adverse events, limiting long-term use in most patients.
Unmet NeedsThere are no FDA approved treatments for CSA, and current standard of care options are invasive, inadequate, and can cause pain, scarring, and lesion recurrence.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $11.17 and its highest was $63.12 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $651.08M.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 191 days.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.741 by -$0.119.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 11,059,665 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.741. Following the earnings report the stock price went up 3.271%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$73.00 (26.54% Upside)
$73.00 (26.54% Upside)
Hedge Fund Trend
Increased
By 243.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.0%
Last 30 Days ▲ 21.0%
Last 30 Days ▲ 21.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
249.84%
12-Months-Change
Fundamentals
Return on Equity
-68.21%
Trailing 12-Months
Asset Growth
194.39%
Trailing 12-Months
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q2 2025
0:00 / 0:00
PVLA Stock 12 Month Forecast
Average Price Target
$73.00
▲(26.54% Upside)
Technical Analysis
Ownership Overview
2.31% Insiders
2.63% Mutual Funds
37.18% Other Institutional Investors
54.24% Public Companies and Individual Investors
Options Prices
Currently, No data available
---